Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute mye...
September 15, 2026
Share
Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.